The abstract is read at the publisher; the summary is JClub's.
In BAP1-deficient uveal melanoma preclinical models, the CDK7/9 plus CK1α inhibitor A51 induces cell death, linked to MCL1 down-regulation and improved liver tumor survival outcomes.
- Why it matters: Advanced-stage uveal melanoma often progresses in the liver with limited options, and BAP1-deficient tumors show transcriptional rewiring that may be targetable.
- What they did: Drug screening and DepMap analysis identified strong UM dependence on CDK7/9; SY-5609 inhibited growth, while A51 caused cell cycle arrest and cell death, with RNA-seq/protein arrays implicating MCL1.
- The result: MCL1 depletion enhanced SY-5609-associated death and MCL1 overexpression rescued A51-associated death; in a non-invasive in vivo liver injection model, A51 reduced tumor onset and improved overall survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.